Department of Natural Sciences, Lebanese American University, PO Box 36, Byblos, Lebanon.
Department of Natural Sciences, Lebanese American University, PO Box 36, Byblos, Lebanon.
Fungal Genet Biol. 2021 Aug;153:103575. doi: 10.1016/j.fgb.2021.103575. Epub 2021 May 24.
Hospital infections caused by the opportunistic fungus Candida albicans are increasingly common and life threatening. The first line of defense consists of administering antifungal drugs such as azoles including fluconazole that prevent ergosterol biosynthesis. C. albicans is rapidly developing resistance towards antifungal drugs through various mechanisms including mutations in ERG11 which is a gene involved in the ergosterol biosynthesis pathway. These mutations prevent the binding of the drug and inactivate ergosterol synthesis. Alternatively, upregulation of cell membrane ergosterol content generates resistance by countering the effect of the drug. In this study we sequenced the ERG11 gene in 6 fluconazole sensitive and 8 fluconazole resistant C. albicans isolates recovered from clinical settings in Lebanon and quantified the ergosterol content of their plasma membranes to identify mechanisms linked to fluconazole resistance. A number of pathogenicity attributes were also analyzed to determine any correlation with fluconazole resistance. Our results revealed an increase in ergosterol content in the fluconazole resistant isolates. In addition, we identified both novel and previously reported amino acid substitutions in ERG11 as well as frameshift mutations that might contribute to resistance. The fluconazole resistant isolates did not exhibit an increased virulence potential in a mouse model of systemic infection and showed decreased in vitro potential to form biofilms. No discrepancy between drug resistant and sensitive isolates to cell surface disrupting agents was observed. This approach is the first of its kind to be carried out in Lebanon to identify possible mechanisms and phenotypes of drug resistant C. albicans isolates.
白色念珠菌引起的医院感染越来越普遍,且具有生命威胁。第一道防线包括使用抗真菌药物,如唑类药物(包括氟康唑),以阻止麦角固醇生物合成。白色念珠菌通过各种机制(包括参与麦角固醇生物合成途径的 ERG11 基因突变)迅速对抗真菌药物产生耐药性。这些突变阻止了药物的结合并使麦角固醇合成失活。或者,通过抵消药物的作用,上调细胞膜麦角固醇含量产生耐药性。在这项研究中,我们对从黎巴嫩临床环境中回收的 6 株氟康唑敏感和 8 株氟康唑耐药的白色念珠菌分离株进行了 ERG11 基因测序,并定量了它们质膜中的麦角固醇含量,以确定与氟康唑耐药相关的机制。还分析了许多致病性特征,以确定与氟康唑耐药性的任何相关性。我们的结果表明,氟康唑耐药分离株中的麦角固醇含量增加。此外,我们在 ERG11 中鉴定了新的和以前报道的氨基酸取代以及可能导致耐药性的移码突变。氟康唑耐药分离株在系统性感染的小鼠模型中没有表现出增加的毒力潜力,并且在体外形成生物膜的潜力降低。未观察到细胞表面破坏剂的耐药和敏感分离株之间的差异。这种方法是在黎巴嫩首次进行的,旨在确定耐药白色念珠菌分离株的可能机制和表型。